OncoMatch/Clinical Trials/NCT05060796
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
Is NCT05060796 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells for non small cell lung cancer.
Treatment: CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells — This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR expression (IHC score 2+ or more)
the immuno- histochemical test must determine that the expression of EGFR in the tumor site of the patient reaches the positive standard and the score is 2 + or more
Required: CXCL13 expression (positive rate ≥ 10%)
Pathological results suggest that CXCL13 factor positive rate ≥ 10 %
Disease stage
Metastatic disease required
advanced non-small cell lung cancer(Including TKI treatment failure patients); ... The patient has at least one tumor lesion that can be measured (Results available within one month prior to screening period)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: gene therapy
Patients who have previously received any gene therapy product treatment, including CAR-T treatment
Cannot have received: antitumor chemotherapy (other than lymphocyte clearance chemotherapy)
Exception: within 14 days before the EGFR CAR-T infusion
Patients who had undergone antitumor chemotherapy other than lymphocyte clearance chemotherapy within 14 days before the EGFR CAR-T infusion
Cannot have received: other research drugs
Exception: within 30 days before infusion
Screening of patients who had received other research drugs within 30 days before infusion
Cannot have received: radiotherapy
Exception: within 2 weeks before infusion
Patients undergoing radiotherapy ... within 2 weeks before infusion
Cannot have received: TKI treatment
Exception: within 2 weeks before infusion
Patients undergoing ... TKI treatment within 2 weeks before infusion
Lab requirements
Blood counts
White blood cells ≥ 2 × 10^9/L; Platelet ≥ 100 x 10^9/L; Hemoglobin ≥ 100 g/L (subjects can meet this requirement through blood transfusion)
Kidney function
Serum creatinine ≤ 1.6 mg/ml or the creatinine clearance ≥ 40 ml/min/1.73m
Liver function
Total bilirubin < 1.5 times upper limits of normal
Cardiac function
Hemodynamics determined by echocardiography or MUGA are stable and LVEF ≥ 50%
Patients must have evidence of adequate hepatic and renal function ... sufficient bone marrow reserves ... hemodynamics determined by echocardiography or multichannel radionuclide angiography(MUGA) are stable and the left ventricular ejection fraction (LVEF)≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05060796 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, antitumor chemotherapy (other than lymphocyte clearance chemotherapy), other research drugs disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR expression is a required biomarker for enrollment.
Does this trial require CXCL13?
Yes, CXCL13 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages